Hepatitis C and kidney disease: An overview and approach to management

World Journal of Hepatology

Volumn 7, Issue 1, 2015, Pages 78-92

  Azmi, Ahmad Najib ^a   Tan, Soek Siam ^b   Mohamed, Rosmawati ^c  

^a UNIVERSITI SAINS ISLAM MALAYSIA   (Malaysia)

^b Selayang Hospital   (Malaysia)

^c UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Chronic hepatitis C; Kidney disease; Management

Indexed keywords

EID: 84920895538     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i1.78     Document Type: Article

References (134)

1. Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011) 2013; 3: 19-62 [PMID: 25018975 DOI: 10.1038/ kisup.2012.64]
2. WHO. Hepatitis C Factsheets. [Accessed on 2014 August 1]. Available from: URL: http: //www.who.int/mediacentre/ factsheets/fs164/en/
3. Wreghitt TG. Blood-borne virus infections in dialysis units--a review. Rev Med Virol 1999; 9: 101-109 [PMID: 10386337]
4. Chan TM, Lok AS, Cheng IK, Chan RT. Prevalence of hepatitis C virus infection in hemodialysis patients: a longitudinal study comparing the results of RNA and antibody assays. Hepatology 1993; 17: 5-8 [PMID: 7678575]
5. Li WC, Lee YY, Chen IC, Wang SH, Hsiao CT, Loke SS. Age and gender differences in the relationship between hepatitis C infection and all stages of Chronic kidney disease. J Viral Hepat 2014; 21: 706-715 [PMID: 24304473 DOI: 10.1111/ jvh.12199]
6. El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002; 36: 1439-1445 [PMID: 12447870 DOI: 10.1053/jhep.2002.37191]
7. Chen YC, Lin HY, Li CY, Lee MS, Su YC. A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. Kidney Int 2014; 85: 1200-1207 [PMID: 24257691 DOI: 10.1038/ki.2013.455]
8. Lee JJ, Lin MY, Yang YH, Lu SN, Chen HC, Hwang SJ. Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study. Am J Kidney Dis 2010; 56: 23-31 [PMID: 20400217 DOI: 10.1053/ j.ajkd.2010.01.015]
9. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008; (109): S1-99 [PMID: 18382440 DOI: 10.1038/ki.2008.81]
10. Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat 2012; 19: 601-607 [PMID: 22863263 DOI: 10.1111/ j.1365-2893.2012.01633.x]
11. Pawlotsky JM. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development. Semin Liver Dis 2014; 34: 22-29 [PMID: 24782255 DOI: 10.1055/ s-0034-1371007]
12. Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V, Yamamoto AM, Camproux AC, Hausfater P, Musset L, Veyssier P, Raguin G, Piette JC. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 2000; 79: 47-56 [PMID: 10670409]
13. Tsui JI, Vittinghoff E, Shlipak MG, Bertenthal D, Inadomi J, Rodriguez RA, O'Hare AM. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med 2007; 167: 1271-1276 [PMID: 17592100 DOI: 10.1001/archinte.167.12.1271]
14. Lee JJ, Lin MY, Chang JS, Hung CC, Chang JM, Chen HC, Yu ML, Hwang SJ. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One 2014; 9: e100790 [PMID: 24971499 DOI: 10.1371/journal.pone.0100790]
15. Dai CY, Yeh ML, Huang CF, Hou CH, Hsieh MY, Huang JF, Lin IL, Lin ZY, Chen SC, Wang LY, Chuang WL, Yu ML, Tung HD. Chronic hepatitis C infection is associated with insulin resistance and lipid profiles. J Gastroenterol Hepatol 2013; Epub ahead of print [PMID: 23808794 DOI: 10.1111/ jgh.12313]
16. Ozkok A, Yildiz A. Hepatitis C virus associated glomerulopathies. World J Gastroenterol 2014; 20: 7544-7554 [PMID: 24976695 DOI: 10.3748/wjg.v20.i24.7544]
17. Roccatello D, Fornasieri A, Giachino O, Rossi D, Beltrame A, Banfi G, Confalonieri R, Tarantino A, Pasquali S, Amoroso A, Savoldi S, Colombo V, Manno C, Ponzetto A, Moriconi L, Pani A, Rustichelli R, Di Belgiojoso GB, Comotti C, Quarenghi MI. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007; 49: 69-82 [PMID: 17185147 DOI: 10.1053/j.ajkd.2006.09.015]
18. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med 2012; 366: 1119-1131 [PMID: 22435371 DOI: 10.1056/NEJMra1108178]
19. Bataille S, Kaplanski G, Boucraut J, Halfon P, Camus C, Daniel L, Burtey S, Berland Y, Dussol B. Membranoproliferative glomerulonephritis and mixed cryoglobulinemia after hepatitis C virus infection secondary to glomerular NS3 viral antigen deposits. Am J Nephrol 2012; 35: 134-140 [PMID: 22248563 DOI: 10.1159/000335375]
20. Cao Y, Zhang Y, Wang S, Zou W. Detection of the hepatitis C virus antigen in kidney tissue from infected patients with various glomerulonephritis. Nephrol Dial Transplant 2009; 24: 2745-2751 [PMID: 19377056 DOI: 10.1093/ndt/gfp167]
21. Fabrizi F, Lunghi G, Messa P, Martin P. Therapy of hepatitis C virus-associated glomerulonephritis: current approaches. J Nephrol 2008; 21: 813-825 [PMID: 19034865]
22. Monti G, Galli M, Invernizzi F, Pioltelli P, Saccardo F, Monteverde A, Pietrogrande M, Renoldi P, Bombardieri S, Bordin G. Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM 1995; 88: 115-126 [PMID: 7704562]
23. Tarantino A, Campise M, Banfi G, Confalonieri R, Bucci A, Montoli A, Colasanti G, Damilano I, D'Amico G, Minetti L. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47: 618-623 [PMID: 7723249]
24. Castillo I, Martinez-Ara J, Olea T, Bartolomé J, Madero R, Hernández E, Bernis C, Aguilar A, Quiroga JA, Carreño V, Selgas R. High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies. Kidney Int 2014; 86: 619-624 [PMID: 24646855 DOI: 10.1038/ki.2014.68]
25. Kong D, Wu D, Wang T, Li T, Xu S, Chen F, Jin X, Lou G. Detection of viral antigens in renal tissue of glomerulonephritis patients without serological evidence of hepatitis B virus and hepatitis C virus infection. Int J Infect Dis 2013; 17: e535-e538 [PMID: 23474175 DOI: 10.1016/j. ijid.2013.01.017]
26. Omata M, Kanda T, Yu M-L, Yokosuka O, Lim S-G, Jafri W, Tateishi R, Hamid SS, Chuang W-L, Chutaputti A. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepa Inter 2012; 6: 409-435 [DOI: 10.1007/s12072-012-9342-y]
27. Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, Rayner HC, Greenwood RN, Akiba T, Young EW. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004; 65: 2335-2342 [PMID: 15149347 DOI: 10.1111/j.1523-1755.2004.00649.x]
28. Johnson DW, Dent H, Yao Q, Tranaeus A, Huang CC, Han DS, Jha V, Wang T, Kawaguchi Y, Qian J. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transplant 2009; 24: 1598-1603 [PMID: 19096083 DOI: 10.1093/ndt/gfn684]
29. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18: 52-61 [PMID: 15663766 DOI: 10.1111/j.1525-139X.2005.18108.x]
30. Di Napoli A, Pezzotti P, Di Lallo D, Petrosillo N, Trivelloni C, Di Giulio S. Epidemiology of hepatitis C virus among longterm dialysis patients: a 9-year study in an Italian region. Am J Kidney Dis 2006; 48: 629-637 [PMID: 16997059 DOI: 10.1053/ j.ajkd.2006.07.004]
31. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Metaanalysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 2004; 20: 1271-1277 [PMID: 15606388 DOI: 10.1111/j.1365-2036.2004.02290.x]
32. Chou CY, Wang IK, Liu JH, Lin HH, Wang SM, Huang CC. Comparing survival between peritoneal dialysis and hemodialysis treatment in ESRD patients with chronic hepatitis C infection. Perit Dial Int 2010; 30: 86-90 [PMID: 20056985]
33. Bose B, McDonald SP, Hawley CM, Brown FG, Badve SV, Wiggins KJ, Bannister KM, Boudville N, Clayton P, Johnson DW. Effect of dialysis modality on survival of hepatitis C-infected ESRF patients. Clin J Am Soc Nephrol 2011; 6: 2657-2661 [PMID: 21903989 DOI: 10.2215/CJN.02200311]
34. Fabrizi F, Martin P, Dixit V, Messa P. Meta-analysis of observational studies: hepatitis C and survival after renal transplant. J Viral Hepat 2014; 21: 314-324 [PMID: 24716634 DOI: 10.1111/jvh.12148]
35. Aline-Fardin A, Rifle G, Martin L, Justrabo E, Bour JB, D'Athis P, Tanter Y, Mousson C. Recurent and de novo membranous glomerulopathy after kidney transplantation. Transplant Proc 2009; 41: 669-671 [PMID: 19328952 DOI: 10.1016/j.transproceed.2009.01.042]
36. Morales JM. Hepatitis C virus infection and renal disease after renal transplantation. Transplant Proc 2004; 36: 760-762 [PMID: 15110654 DOI: 10.1016/j.transproceed.2004.03.041]
37. Cruzado JM, Carrera M, Torras J, Grinyó JM. Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 2001; 1: 171-178 [PMID: 12099366]
38. Delladetsima JK, Boletis JN, Makris F, Psichogiou M, Kostakis A, Hatzakis A. Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection. Liver Transpl Surg 1999; 5: 294-300 [PMID: 10388502 DOI: 10.1002/lt.500050417]
39. Delladetsima JK, Makris F, Psichogiou M, Kostakis A, Hatzakis A, Boletis JN. Cholestatic syndrome with bile duct damage and loss in renal transplant recipients with HCV infection. Liver 2001; 21: 81-88 [PMID: 11318976]
40. de Oliveira Uehara SN, Emori CT, da Silva Fucuta Pereira P, Perez RM, Pestana JO, Lanzoni VP, e Silva IS, Silva AE, Ferraz ML. Histological evolution of hepatitis C virus infection after renal transplantation. Clin Transplant 2012; 26: 842-848 [PMID: 22594774 DOI: 10.1111/j. 1399-0012.2012.0163 5.x]
41. Roth D, Gaynor JJ, Reddy KR, Ciancio G, Sageshima J, Kupin W, Guerra G, Chen L, Burke GW. Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol 2011; 22: 1152-1160 [PMID: 21546575 DOI: 10.1681/ASN.2010060668]
42. Maluf DG, Fisher RA, King AL, Gibney EM, Mas VR, Cotterell AH, Shiffman ML, Sterling RK, Behnke M, Posner MP. Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival. Transplantation 2007; 83: 853-857 [PMID: 17460555 DOI: 10.1097/01. tp.0000259725.96694.0a]
43. Pereira BJ, Natov SN, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, Levey AS. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1998; 53: 1374-1381 [PMID: 9573555 DOI: 10.1046/ j.1523-1755.1998.00883.x]
44. Pereira BJ, Wright TL, Schmid CH, Bryan CF, Cheung RC, Cooper ES, Hsu H, Heyn-Lamb R, Light JA, Norman DJ. Screening and confirmatory testing of cadaver organ donors for hepatitis C virus infection: a U.S. National Collaborative Study. Kidney Int 1994; 46: 886-892 [PMID: 7527878]
45. Kucirka LM, Peters TG, Segev DL. Impact of donor hepatitis C virus infection status on death and need for liver transplant in hepatitis C virus-positive kidney transplant recipients. Am J Kidney Dis 2012; 60: 112-120 [PMID: 22560841 DOI: 10.1053/j.ajkd.2012.03.015]
46. Abbott KC, Lentine KL, Bucci JR, Agodoa LY, Peters TG, Schnitzler MA. The impact of transplantation with deceased donor hepatitis c-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant 2004; 4: 2032-2037 [PMID: 15575906 DOI: 10.1046/j.1600-6143.2004.00606.x]
47. Widell A, Månsson S, Persson NH, Thysell H, Hermodsson S, Blohme I. Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCV-infected kidney. Transplantation 1995; 60: 642-647 [PMID: 7570969]
48. Wolf PL, Williams D, Coplon N, Coulson AS. Low aspartate transaminase activity in serum of patients undergoing chronic hemodialysis. Clin Chem 1972; 18: 567-568 [PMID: 5026769]
49. Schrader C, Schielke A, Ellerbroek L, Johne R. PCR inhibitors - occurrence, properties and removal. J Appl Microbiol 2012; 113: 1014-1026 [PMID: 22747964 DOI: 10.1111/ j.1365-2672.2012.05384.x]
50. Liu CH, Liang CC, Huang KW, Liu CJ, Chen SI, Lin JW, Hung PH, Tsai HB, Lai MY, Chen PJ, Chen JH, Chen DS, Kao JH. Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. Clin J Am Soc Nephrol 2011; 6: 1057-1065 [PMID: 21393486 DOI: 10.2215/ CJN.04320510]
51. Pawa S, Ehrinpreis M, Mutchnick M, Janisse J, Dhar R, Siddiqui FA. Percutaneous liver biopsy is safe in chronic hepatitis C patients with end-stage renal disease. Clin Gastroenterol Hepatol 2007; 5: 1316-1320 [PMID: 17904916 DOI: 10.1016/j.cgh.2007.07.010]
52. Fabrizi F, Messa P, Martin P. Current status of renal transplantation from HCV-positive donors. Int J Artif Organs 2009; 32: 251-261 [PMID: 19569034]
53. Sterling RK, Sanyal AJ, Luketic VA, Stravitz RT, King AL, Post AB, Mills AS, Contos MJ, Shiffman ML. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 1999; 94: 3576-3582 [PMID: 10606322 DOI: 10.1111/j. 1572-0241.1999.01 649.x]
54. Martin P, Carter D, Fabrizi F, Dixit V, Conrad AJ, Artinian L, Peacock V, Han S, Wilkinson A, Lassman CR, Danovitch G. Histopathological features of hepatitis C in renal transplant candidates [see comment]. Transplantation 2000; 69: 1479-1484 [PMID: 10798774]
55. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014; 61: 373-395 [PMID: 24818984 DOI: 10.1016/ j.jhep.2014.05.001]
56. Jiang Y, Huang E, Mehrnia A, Kamgar M, Pham PT, Ogunorunyinka O, Brown I, Danovitch GM, Bunnapradist S. Can aminotransferase-to-platelet ratio index and other noninvasive markers effectively reduce liver biopsies for renal transplant evaluation of hepatitis C virus-positive patients? Nephrol Dial Transplant 2014; 29: 1247-1252 [PMID: 24353319 DOI: 10.1093/ndt/gft485]
57. Liu CH, Liang CC, Liu CJ, Hsu SJ, Lin JW, Chen SI, Hung PH, Tsai HB, Lai MY, Chen PJ, Chen JH, Chen DS, Kao JH. The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C. Kidney Int 2010; 78: 103-109 [PMID: 20357753 DOI: 10.1038/ki.2010.74]
58. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007; 102: 2589-2600 [PMID: 17850410 DOI: 10.1111/j. 1572-0241.20 07.01466.x]
59. Goodkin DA, Bieber B, Gillespie B, Robinson BM, Jadoul M. Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol 2013; 38: 405-412 [PMID: 24192505 DOI: 10.1159/000355615]
60. Gürsoy M, Güvener N, Köksal R, Karavelioglu D, Baysal C, Ozdemir N, Boyacioglu S, Bilgin N, Erdal R. Impact of HCV infection on development of posttransplantation diabetes mellitus in renal allograft recipients. Transplant Proc 2000; 32: 561-562 [PMID: 10812113]
61. Mahmoud IM, Sobh MA, El-Habashi AF, Sally ST, El-Baz M, El-Sawy E, Ghoneim MA. Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course. Nephron Clin Pract 2005; 100: c133-c139 [PMID: 15855796 DOI: 10.1159/000085442]
62. Cruzado JM, Casanovas-Taltavull T, Torras J, Baliellas C, Gil-Vernet S, Grinyó JM. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 2003; 3: 357-360 [PMID: 12614294]
63. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593 [PMID: 23268517 DOI: 10.1001/jama.2012.144878]
64. Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, Liu YY, Wu CY. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014; 59: 1293-1302 [PMID: 24122848 DOI: 10.1002/hep. 26892]
65. Gordon CE, Uhlig K, Schmid CH, Levey AS, Wong JB. Longterm viral negativity after interferon for chronic hepatitis C virus infection in hemodialysis. Clin J Am Soc Nephrol 2011; 6: 2226-2234 [PMID: 21784816 DOI: 10.2215/CJN.00410111]
66. Pegasys Prescribing Information. [Accessed on 15 July 2014]. Available from: URL: http: //www.gene.com/download/ pdf/pegasys_prescribing.pdf
67. Gupta SK, Pittenger AL, Swan SK, Marbury TC, Tobillo E, Batra V, Sack M, Glue P, Jacobs S, Affrime M. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol 2002; 42: 1109-1115 [PMID: 12362925]
68. Brennan BJ, Wang K, Blotner S, Magnusson MO, Wilkins JJ, Martin P, Solsky J, Nieforth K, Wat C, Grippo JF. Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. Antimicrob Agents Chemother 2013; 57: 6097-6105 [PMID: 24080649 DOI: 10.1128/AAC.00608-13]
69. Alavian SM, Tabatabaei SV. Meta-analysis of factors associated with sustained viral response in patients on hemodialysis treated with standard or pegylated interferon for hepatitis C infection. Iran J Kidney Dis 2010; 4: 181-194 [PMID: 20622305]
70. Yu YC, Wang Y, He CL, Wang MR, Wang YM. Management of hepatitis C virus infection in hemodialysis patients. World J Hepatol 2014; 6: 419-425 [PMID: 25018852 DOI: 10.4254/wjh. v6.i6.419]
71. Njoroge FG, Chen KX, Shih NY, Piwinski JJ. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc Chem Res 2008; 41: 50-59 [PMID: 18193821 DOI: 10.1021/ar700109k]
72. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]
73. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]
74. Treitel M, Marbury T, Preston RA, Triantafyllou I, Feely W, O'Mara E, Kasserra C, Gupta S, Hughes EA. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet 2012; 51: 619-628 [PMID: 22799589 DOI: 10.2165/11633440-000000000-00000]
75. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428 [PMID: 21696308 DOI: 10.1056/NEJMoa1013086]
76. Matthews SJ, Lancaster JW. Telaprevir: a hepatitis C NS3/ 4A protease inhibitor. Clin Ther 2012; 34: 1857-1882 [PMID: 22951253 DOI: 10.1016/j.clinthera.2012.07.011]
77. Vertex. Incivek (Telaprevir) Prescribing Information. [Accessed on 27th August 2014]. Available from: URL: http: //pi.vrtx.com/files/uspi_telaprevir.pdf
78. Mauss S, Hueppe D, Alshuth U. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology 2014; 59: 46-48 [PMID: 23813604 DOI: 10.1002/hep.26602]
79. Virlogeux V, Pradat P, Bailly F, Funingana G, Gonçalves F, Maynard M, Hartig-Lavie K, Amiri M, Zoulim F. Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score. J Viral Hepat 2014; 21: e98-e107 [PMID: 24612466 DOI: 10.1111/jvh.12237]
80. Loustaud-Ratti V, Rousseau A, Carrier P, Vong C, Chambaraud T, Jacques J, Debette-Gratien M, Sautereau D, Essig M. eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance? Liver Int 2014; Epub ahead of print [PMID: 25039814 DOI: 10.1111/ liv.12631]
81. Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, Horban A, Brown A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Scott J, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146: 1669-79.e3 [PMID: 24602923 DOI: 10.1053/j.gastro.2014.02.051]
82. Janssen. Olysio (Simeprevir) Prescribing Information. [Accessed 3rd August 2014]. Available from: URL: http: //www.olysio.com/shared/product/olysio/prescribinginformation. pdf
83. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887 [PMID: 23607594 DOI: 10.1056/NEJMoa1214853]
84. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877 [PMID: 23607593 DOI: 10.1056/NEJMoa1214854]
85. Gilead. Sovaldi (Sofosbuvir) Prescribing Information. [Accessed on 2nd August 2014]. Available from: URL: http: //www.gilead.com/~/media/Files/pdfs/medicines/liverdisease/ sovaldi/sovaldi_pi.pdf
86. AASLD/IDSA/IAS-USA. Unique Patient Populations: Renal Impairment Box. Summary of recommendations for Patients with Renal Impairment Including Severe Renal Impairment (CrCl <30 ML/min) or ESRD Requiring Hemodialysis or Peritoneal Dialysis. [Accessed 26th August 2014]. Available from: URL: http: //hcvguidelines.org/full-report/uniquepatient-populations-renal-impairment-box-summaryrecommendations-patients-renal
87. AASLD/IDSA/IAS-USA. When and in Whom to Initiate HCV Therapy. [Accessed 26th August 2014]. Available from: URL: http: //hcvguidelines.org/full-report/when-andwhom-initiate-hcv-therapy
88. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330: 877-884 [PMID: 8114857 DOI: 10.1056/NEJM199403313301301]
89. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857-1863 [PMID: 9217756]
90. Fabrizi F, Dixit V, Messa P. Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies. J Med Virol 2013; 85: 1019-1027 [PMID: 23588727 DOI: 10.1002/jmv.23562]
91. Fabrizi F, Donato F, Messa P. Hepatitis C virus infection and glomerular disease. Minerva Urol Nefrol 2014; 66: 139-149 [PMID: 24988205]
92. Fabrizi F, Plaisier E, Saadoun D, Martin P, Messa P, Cacoub P. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis 2013; 61: 623-637 [PMID: 23102733 DOI: 10.1053/j.ajkd.2012.08.040]
93. Bruchfeld A, Lindahl K, Ståhle L, Söderberg M, Schvarcz R. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003; 18: 1573-1580 [PMID: 12897097]
94. Alric L, Plaisier E, Thébault S, Péron JM, Rostaing L, Pourrat J, Ronco P, Piette JC, Cacoub P. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004; 43: 617-623 [PMID: 15042538]
95. Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P. Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 2006; 54: 3696-3706 [PMID: 17075881 DOI: 10.1002/art.22168]
96. Garini G, Allegri L, Lannuzzella F, Vaglio A, Buzio C. HCVrelated cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies. Acta Biomed 2007; 78: 51-59 [PMID: 17687818]
97. Saadoun D, Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, Schoindre Y, Coppéré B, Blanc F, Musset L, Piette JC, Rosenzwajg M, Cacoub P. Rituximab plus Peg-interferonalpha/ ribavirin compared with Peg-interferon-alpha/ ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010; 116: 326-334; quiz 504-505 [PMID: 20439619 DOI: 10.1182/blood-2009-10-248518]
98. Naarendorp M, Kallemuchikkal U, Nuovo GJ, Gorevic PD. Longterm efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection. J Rheumatol 2001; 28: 2466-2473 [PMID: 11708420]
99. Casato M, Agnello V, Pucillo LP, Knight GB, Leoni M, Del Vecchio S, Mazzilli C, Antonelli G, Bonomo L. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997; 90: 3865-3873 [PMID: 9354653]
100. Zuckerman E, Keren D, Slobodin G, Rosner I, Rozenbaum M, Toubi E, Sabo E, Tsykounov I, Naschitz JE, Yeshurun D. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 2000; 27: 2172-2178 [PMID: 10990230]
101. Fabrizi F, Bruchfeld A, Mangano S, Dixit V, Messa P, Martin P. Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials. Int J Artif Organs 2007; 30: 212-219 [PMID: 17417760]
102. Feng B, Eknoyan G, Guo ZS, Jadoul M, Rao HY, Zhang W, Wei L. Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a metaanalysis. Nephrol Dial Transplant 2012; 27: 640-646 [PMID: 21558431 DOI: 10.1093/ndt/gfr236]
103. Quartuccio L, Soardo G, Romano G, Zaja F, Scott CA, De Marchi G, Fabris M, Ferraccioli G, De Vita S. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford) 2006; 45: 842-846 [PMID: 16418196 DOI: 10.1093/rheumatology/kel004]
104. Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 2008; 67: 283-287 [PMID: 17644544 DOI: 10.1136/ ard.2006.065565]
105. Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, Zilio P, Vernocchi A, Massazza M, Vendramin G. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330: 751-756 [PMID: 8107741 DOI: 10.1056/NEJM199403173301104]
106. Dammacco F, Sansonno D, Han JH, Shyamala V, Cornacchiulo V, Iacobelli AR, Lauletta G, Rizzi R. Natural interferonalpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a longterm, randomized, controlled study. Blood 1994; 84: 3336-3343 [PMID: 7524736]
107. Mahale P, Kontoyiannis DP, Chemaly RF, Jiang Y, Hwang JP, Davila M, Torres HA. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol 2012; 57: 1177-1185 [PMID: 22871500 DOI: 10.1016/ j.jhep.2012.07.031]
108. Koziolek MJ, Scheel A, Bramlage C, Groene HJ, Mueller GA, Strutz F. Effective treatment of hepatitis C-associated immune-complex nephritis with cryoprecipitate apheresis and antiviral therapy. Clin Nephrol 2007; 67: 245-249 [PMID: 17474561]
109. Saadoun D, Delluc A, Piette JC, Cacoub P. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 2008; 20: 23-28 [PMID: 18281853 DOI: 10.1097/BOR.0b013e3282f1330c]
110. Chapter 9: Infection-related glomerulonephritis. Kidney Int Suppl (2011) 2012; 2: 200-208 [PMID: 25018934 DOI: 10.1038/ kisup.2012.22]
111. Cid MC, Hernández-Rodríguez J, Robert J, del Río A, Casademont J, Coll-Vinent B, Grau JM, Kleinman HK, Urbano-Márquez A, Cardellach F. Interferon-alpha may exacerbate cryoblobulinemia-related ischemic manifestations: an adverse effect potentially related to its anti-angiogenic activity. Arthritis Rheum 1999; 42: 1051-1055 [PMID: 10323463 DOI: 10.1002/1529-0131(199905)42:5<1051:: AID-ANR26>3.0.CO;2-Q]
112. Espinosa M, Martin-Malo A, Alvarez de Lara MA, Gonzalez R, Rodriguez M, Aljama P. Natural history of acute HCV infection in hemodialysis patients. Clin Nephrol 2002; 58: 143-150 [PMID: 12227687]
113. Gürsoy M, Gür G, Arslan H, Ozdemir N, Boyacioglu S. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepat 2001; 8: 70-77 [PMID: 11155154]
114. Furusyo N, Hayashi J, Kakuda K, Ariyama I, Kanamoto-Tanaka Y, Shimizu C, Etoh Y, Shigematsu M, Kashiwagi S. Acute hepatitis C among Japanese hemodialysis patients: a prospective 9-year study. Am J Gastroenterol 2001; 96: 1592-1600 [PMID: 11374705 DOI: 10.1111/j. 1572-0241.2001.03 701.x]
115. Liu CH, Liang CC, Liu CJ, Lin JW, Chen SI, Hung PH, Tsai HB, Lai MY, Chen PJ, Chen DS, Kao JH. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C. Clin Infect Dis 2010; 51: 541-549 [PMID: 20645865 DOI: 10.1086/655682]
116. Fabrizi F, Dixit V, Messa P, Martin P. Interferon therapy of acute hepatitis C in dialysis patients: meta-analysis. J Viral Hepat 2012; 19: 784-791 [PMID: 23043385 DOI: 10.1111/ j.1365-2893.2012.01607.x]
117. Fabrizi F, Dixit V, Messa P, Martin P. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 2008; 15: 79-88 [PMID: 18184190 DOI: 10.1111/j.1365-2893.2007.00907.x]
118. Fabrizi F, Dixit V, Messa P, Martin P. Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials. J Med Virol 2010; 82: 768-775 [PMID: 20336712 DOI: 10.1002/jmv.21542]
119. Rostaing L, Chatelut E, Payen JL, Izopet J, Thalamas C, Ton-That H, Pascal JP, Durand D, Canal P. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9: 2344-2348 [PMID: 9848789]
120. Tan SS, Abu Hassan MR, Abdullah A, Ooi BP, Korompis T, Merican MI. Safety and efficacy of an escalating dose regimen of pegylated interferon alpha-2b in the treatment of haemodialysis patients with chronic hepatitis C. J Viral Hepat 2010; 17: 410-418 [PMID: 19758272 DOI: 10.1111/ j.1365-2893.2009.01191.x]
121. Liu CH, Huang CF, Liu CJ, Dai CY, Liang CC, Huang JF, Hung PH, Tsai HB, Tsai MK, Chen SI, Lin JW, Yang SS, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Yu ML, Kao JH. Pegylated interferon-a2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med 2013; 159: 729-738 [PMID: 24297189 DOI: 10.7326 /0003-4819-159-11-201312030-00005]
122. Fabrizi F, Dixit V, Martin P, Messa P. Combined antiviral therapy of hepatitis C virus in dialysis patients: metaanalysis of clinical trials. J Viral Hepat 2011; 18: e263-e269 [PMID: 21108701 DOI: 10.1111/j.1365-2893.2010.01405.x]
123. Dumortier J, Guillaud O, Gagnieu MC, Janbon B, Juillard L, Morelon E, Leroy V. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? J Clin Virol 2013; 56: 146-149 [PMID: 23149155 DOI: 10.1016/j. jcv.2012.10.009]
124. Wiegand J, Maasoumy B, Buggisch P, Buslau A, Schiefke I, Berg T, Wedemeyer H, Sarrazin C, Hinrichsen H. Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis. Aliment Pharmacol Ther 2014; 39: 1342-1344 [PMID: 24803258 DOI: 10.1111/apt.12748]
125. Rostaing L, Izopet J, Sandres K, Cisterne JM, Puel J, Durand D. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation 2000; 69: 991-994 [PMID: 10755563]
126. Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, Lau JY, Williams R. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167-177 [PMID: 8536853]
127. Okoh EJ, Bucci JR, Simon JF, Harrison SA. HCV in patients with end-stage renal disease. Am J Gastroenterol 2008; 103: 2123-2134 [PMID: 18796105 DOI: 10.1111/j. 1572-0241.2008.01 981.x]
128. Wei F, Liu J, Liu F, Hu H, Ren H, Hu P. Interferon-based anti-viral therapy for hepatitis C virus infection after renal transplantation: an updated meta-analysis. PLoS One 2014; 9: e90611 [PMID: 24699257 DOI: 10.1371/journal.pone.0090611]
129. Baid S, Tolkoff-Rubin N, Saidman S, Chung R, Williams WW, Auchincloss H, Colvin RB, Delmonico FL, Cosimi AB, Pascual M. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 2003; 3: 74-78 [PMID: 12492714]
130. Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, Symonds WT. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 13: 1601-1605 [PMID: 23593993 DOI: 10.1111/ajt.12209]
131. Merck. Victrelis Prescribing Information. [Accessed 5th October 2014]. Available from: URL: http: //www.merck. com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf
132. AASLD/IDSA/IAS-USA. Recommendations for Testing, Managing, and Treating Hepatitis C. [accessed on 26th August 2014]. Available from: URL: http: //hcvguidelines. org/full-report-view
133. Janssen R & D. A study of pharmacokinetics, efficacy, safety, tolerability, of the combination of simeprevir (TMC435), daclatasvir (BMS-790052), and ribavirin (RBV) in patients with recurrent chronic hepatitis C genotype 1b infection after orthotopic liver transplantation (posted 2013b). [Accessed on 2 October 2014]. Available from: URL: http: //www. clinicaltrials.gov/ct2/show/NCT01938625
134. ClinicalTrials.gov. Clinical Trials on Chronic Hepatitis C. [Accessed 26th August 2014]. Available from: URL: http: // clinicaltrials.gov/